Terug
37
4
Ook genoteerd als
SGIOY
OTC
Dagbereik
€ 21,45
€ 21,45
52-Weeksbereik
€ 14,25
€ 26,00
Volume
471
50D / 200D Gem.
€ 21,12
/
€ 17,96
Vorige Slotkoers
€ 18,00
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,1 | 0,4 |
| P/B | 0,0 | 2,9 |
| ROE % | 13,1 | 3,8 |
| Net Margin % | 38,9 | 3,9 |
| Rev Growth 5Y % | 10,2 | 10,0 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 263,73
€ 220,71 – € 286,42
|
730 B | 2 |
| FY2029 |
€ 276,54
€ 231,43 – € 300,33
|
740 B | 4 |
| FY2028 |
€ 288,94
€ 241,82 – € 313,80
|
700 B | 3 |
Belangrijkste Punten
Revenue grew 10,20% annually over 5 years — strong growth
ROE of 13,12% — decent returns on equity
Net margin of 38,89% shows strong profitability
Debt/Equity of 0,02 — conservative balance sheet
Generating 143,36B in free cash flow
P/E of 0,11 — trading at a low valuation
Groei
Revenue Growth (5Y)
10,20%
Revenue (1Y)0,73%
Earnings (1Y)5,19%
FCF Growth (3Y)0,95%
Kwaliteit
Return on Equity
13,12%
ROIC8,49%
Net Margin38,89%
Op. Margin35,73%
Veiligheid
Debt / Equity
0,02
Current Ratio6,63
Interest Coverage17,35
Waardering
P/E Ratio
0,11
P/B Ratio0,01
EV/EBITDA-2,14
Dividend Yield0,07%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 0,73% | Revenue Growth (3Y) | 1,35% |
| Earnings Growth (1Y) | 5,19% | Earnings Growth (3Y) | -4,01% |
| Revenue Growth (5Y) | 10,20% | Earnings Growth (5Y) | 11,10% |
| Profitability | |||
| Revenue (TTM) | 438,27B | Net Income (TTM) | 170,44B |
| ROE | 13,12% | ROA | 11,10% |
| Gross Margin | 85,44% | Operating Margin | 35,73% |
| Net Margin | 38,89% | Free Cash Flow (TTM) | 143,36B |
| ROIC | 8,49% | FCF Growth (3Y) | 0,95% |
| Safety | |||
| Debt / Equity | 0,02 | Current Ratio | 6,63 |
| Interest Coverage | 17,35 | Dividend Yield | 0,07% |
| Valuation | |||
| P/E Ratio | 0,11 | P/B Ratio | 0,01 |
| P/S Ratio | 0,04 | PEG Ratio | 0,50 |
| EV/EBITDA | -2,14 | Dividend Yield | 0,07% |
| Market Cap | 18,25B | Enterprise Value | -334,66B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 438,27B | 435,08B | 426,68B | 335,14B | 297,18B |
| Net Income | 170,44B | 162,03B | 184,97B | 114,19B | 111,86B |
| EPS (Diluted) | 600,98 | 558,32 | 621,09 | 378,62 | 364,89 |
| Gross Profit | 374,44B | 377,48B | 364,44B | 279,72B | 244,65B |
| Operating Income | 156,60B | 153,31B | 149,00B | 110,31B | 117,44B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,54T | 1,42T | 1,31T | 1,15T | 998,99B |
| Total Liabilities | 172,85B | 164,36B | 189,92B | 157,32B | 134,44B |
| Shareholders' Equity | 1,36T | 1,24T | 1,10T | 975,66B | 846,11B |
| Total Debt | 21,88B | 11,62B | 9,41B | 6,67B | 7,99B |
| Cash & Equivalents | 374,80B | 358,09B | 309,22B | 254,42B | 276,17B |
| Current Assets | 858,50B | 784,21B | 784,19B | 659,21B | 556,24B |
| Current Liabilities | 129,39B | 133,91B | 158,55B | 124,40B | 100,18B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#500 of 820
#635 of 708
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026